Metagenomi Therapeutics, Inc.
Business
Metagenomi Therapeutics is an in vivo genome editing company developing curative genetic medicines using proprietary signature gene editing systems derived from metagenomics. The company's lead program, MGX-001, targets hemophilia A via site-specific genome integration of the Factor VIII gene into hepatocytes, with preclinical data demonstrating durable, curative levels of Factor VIII activity in non-human primates. The company also pursues secreted protein deficiency indications leveraging the MGX-001 platform and partners with Ionis on cardiometabolic disease targets via gene knockout; it operates across wholly-owned and partnered programs with an in-house cGMP manufacturing facility for clinical-grade nucleases and mRNA.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 25 | 52 | 45 | |
| Research and development | 94 | 109 | 94 | |
| General and administrative | 27 | 32 | 29 | |
| Total operating expenses | 121 | 141 | 123 | |
| Loss from operations | −96 | −89 | −78 | |
| Interest income | 9 | 15 | 15 | |
| Change in fair value of long-term investments | −1 | −9 | 3 | |
| Other expense, net | −91,000 | −207,000 | −74,000 | |
| Total other income, net | 8 | 5 | 18 | |
| Net loss before benefit from income taxes | −88 | −84 | −60 | |
| Benefit from income taxes | 58,000 | 6 | −8 | |
| Net loss | −88 | −78 | −68 | |
| Unrealized gain (loss) on available-for-sale marketable securities | −449,000 | 806,000 | 177,000 | |
| Comprehensive loss | −88 | −77 | −68 | |
| Net loss per share attributable to common stockholders - basic | −2.36 | −2.36 | −20.05 | |
| Net loss per share attributable to common stockholders - diluted | −2.36 | −2.36 | −20.05 | |
| Weighted-average common shares outstanding - basic | 37 | 33 | 3 | |
| Weighted-average common shares outstanding - diluted | 37 | 33 | 3 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 42 | 27 | 141 | — | |
| Available-for-sale marketable securities | 119 | 221 | 131 | — | |
| Accounts receivable | 305,000 | 1 | 2 | — | |
| Prepaid expenses and other current assets | 4 | 8 | 5 | — | |
| Total current assets | 166 | 258 | 278 | — | |
| Property and equipment, net | 12 | 18 | 22 | — | |
| Long-term investments | 2 | 3 | 11 | — | |
| Operating lease right-of-use assets | 35 | 40 | 44 | — | |
| Other assets | 836,000 | 287,000 | 5 | — | |
| Restricted cash | 5 | 5 | 5 | — | |
| Total assets | 221 | 325 | 365 | — | |
| Accounts payable | 1 | 533,000 | 2 | — | |
| Accrued expenses and other current liabilities | 7 | 8 | 11 | — | |
| Current portion of operating lease liabilities | 6 | 6 | 3 | — | |
| Deferred revenue | 9 | 23 | 48 | — | |
| Total current liabilities | 23 | 37 | 69 | — | |
| Non-current portion of operating lease liabilities | 35 | 40 | 45 | — | |
| Deferred revenue, non-current | 3 | 10 | 31 | — | |
| Other non-current liabilities | 2 | 2 | 5 | — | |
| Total liabilities | 63 | 90 | 150 | — | |
| Commitments and contingencies (Note 8) | — | — | 0 | — | |
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized and zero shares issued and outstanding | 0 | 0 | 0 | — | |
| Common stock: $0.0001 par value; 500,000,000 shares authorized; 37,620,668 and 37,418,470 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 4,000 | 4,000 | 0 | — | |
| Additional paid-in-capital | 469 | 457 | 9 | — | |
| Accumulated other comprehensive income | 260,000 | 709,000 | −97,000 | — | |
| Accumulated deficit | −311 | −223 | −145 | — | |
| Total stockholders' equity | 159 | 235 | −136 | −74 | |
| Total liabilities and stockholders' equity | 221 | 325 | 365 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −88 | −78 | −68 | |
| Stock-based compensation expense | 12 | 16 | 7 | |
| Depreciation | 5 | 5 | 4 | |
| Loss on fixed assets write-off | 502,000 | 1 | — | |
| Non-cash lease expense | 5 | 5 | 4 | |
| Amortization of premiums and discounts on available-for-sale marketable securities | −3 | −6 | −8 | |
| Amortization of non-cash collaboration revenue | −212,000 | −2 | −742,000 | |
| Accounts receivable | 952,000 | 1 | −2 | |
| Prepaid expenses and other assets | 4 | −2 | −1 | |
| Accounts payable | 1 | −1 | −84,000 | |
| Income tax payable | — | −3 | 2 | |
| Deferred revenue and collaboration advance | −21 | −47 | −30 | |
| Accrued expenses and other current liabilities | −2 | −893,000 | 2 | |
| Operating lease liabilities | −6 | −3 | −1 | |
| Other non-current liabilities | −58,000 | −3 | 4 | |
| Net cash used in operating activities | −89 | −109 | −91 | |
| Purchases of property and equipment | −574,000 | −3 | −10 | |
| Proceeds from sale of property and equipment | 37,000 | — | — | |
| Purchases of available-for-sale marketable securities | −66 | −306 | −208 | |
| Maturities of available-for-sale marketable securities | 170 | 221 | 264 | |
| Purchases of long-term investments | — | −324,000 | — | |
| Net cash provided by (used in) investing activities | 104 | −88 | 46 | |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | — | 84 | — | |
| Proceeds from issuance of common stock under the ESPP | 202,000 | — | 4 | |
| Payment of deferred financing costs | −558,000 | — | — | |
| Net cash provided by (used in) financing activities | −356,000 | 84 | 1 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 14 | −113 | −45 | |
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | — | 351 | — | |
| Issuance of common stock and restricted common stock in exchange for profits interests upon Reorganization | — | 9 | — | |
| Reclassification of deferred offering costs paid in prior year to stockholders' equity | — | 3 | — | |
| Common shares of Affini-T received for collaboration revenue | — | 2 | — | |
| Cash paid for income taxes net of (refunds) (Note 13) | −2 | 4 | 2 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Metagenomi Therapeutics, Inc.'s CIK number?
Metagenomi Therapeutics, Inc.'s SEC CIK number is 0001785279 (1785279). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Metagenomi Therapeutics, Inc.'s SEC filings?
All of Metagenomi Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Metagenomi Therapeutics, Inc. last report earnings?
Metagenomi Therapeutics, Inc. (MGX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216763). This is Metagenomi Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Metagenomi Therapeutics, Inc.'s most recent earnings 8-K?
Metagenomi Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216763. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Metagenomi Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →